Silo pharma to initiate dose-ranging study of novel intranasal therapeutic spc-15 for the treatment of ptsd

Study to determine therapeutic relevant dose range and pharmacokinetic to be used for first-in-human trial study to determine therapeutic relevant dose range and pharmacokinetic to be used for first-in-human trial
SILO Ratings Summary
SILO Quant Ranking